Clinical Trial Update: Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed Tomography for the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Recurrent Glioblastoma [NA]

View source ↗

Summary

This clinical trial update reports on a completed study that evaluated whether 18F-fluorodeoxyglucose PET and brain perfusion CT can predict bevacizumab efficac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Centre Hospitalier Universitaire de Nīmes | Conditions: Glioblastoma | NA | Status: COMPLETED